AbbVie’s Profit Forecast Cut Sends Shockwaves Through Market

A substantial $2.7 billion charge has delivered a significant blow to biotechnology leader AbbVie, forcing the company to dramatically lower its 2025 earnings guidance just ahead of quarterly results. This unexpected development has left investors questioning what prompted the sudden profit warning and whether the company’s long-term growth narrative remains intact.

The profit forecast revision stems from unanticipated research and development expenses totaling $2.7 billion. These IPR&D (In-Process Research and Development) charges typically emerge from acquisition activities or licensing agreements and have impacted AbbVie’s third-quarter results. Consequently, the company has slashed its adjusted earnings per share projection from the previously anticipated range of $11.88-$12.08 down to just $10.38-$10.58. For the current quarter, management forecasts merely $1.74-$1.78 per... Read more...